Published in Clin Med Insights Gastroenterol on April 10, 2012
Lubiprostone in constipation: clinical evidence and place in therapy. Ther Adv Chronic Dis (2015) 0.78
Luminally Acting Agents for Constipation Treatment: A Review Based on Literatures and Patents. Front Pharmacol (2017) 0.75
CLC chloride channels and transporters: from genes to protein structure, pathology and physiology. Crit Rev Biochem Mol Biol (2008) 5.03
The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol (2002) 3.59
SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol (2004) 2.33
Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther (2008) 2.06
Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol (2006) 1.94
Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther (2012) 1.83
Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator. Gastroenterology (2009) 1.59
Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther (2008) 1.50
Distribution of ClC-2 chloride channel in rat and human epithelial tissues. Am J Physiol Cell Physiol (2002) 1.44
Intestinal permeability and irritable bowel syndrome. Neurogastroenterol Motil (2007) 1.33
Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci (2009) 1.19
Diversity of Cl(-) channels. Cell Mol Life Sci (2006) 1.15
Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. Am J Physiol Gastrointest Liver Physiol (2008) 1.09
Enteric nervous system: sensory physiology, diarrhea and constipation. Curr Opin Gastroenterol (2010) 1.06
Effects of lubiprostone on human uterine smooth muscle cells. Prostaglandins Other Lipid Mediat (2008) 1.05
Lubiprostone stimulates duodenal bicarbonate secretion in rats. Dig Dis Sci (2009) 1.03
ClC-2 chloride secretion mediates prostaglandin-induced recovery of barrier function in ischemia-injured porcine ileum. Gastroenterology (2004) 1.03
Lubiprostone stimulates secretion from tracheal submucosal glands of sheep, pigs, and humans. Am J Physiol Lung Cell Mol Physiol (2009) 1.02
Gender distribution in irritable bowel syndrome is proportional to the severity of constipation relative to diarrhea. Gend Med (2010) 0.93
Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome. Neurogastroenterol Motil (2011) 0.92
Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study. Neurogastroenterol Motil (2011) 0.91
Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome. Int J Womens Health (2010) 0.85
Effect of oral dioctyl sodium sulfosuccinate on intake-output studies of human small and large intestine. Gastroenterology (1985) 0.85
Peripherally acting therapies for the treatment of irritable bowel syndrome. Gastroenterol Clin North Am (2011) 0.83